At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02696 HENLIUS
Not Yet Opened 11-21 16:08:22
20.300
-0.050
-0.25%
High20.450Low20.150Vol230.80K
Open20.300D1 Closing20.350Amplitude1.47%
Mkt Cap11.03BTradable Cap3.31BTotal Shares543.49M
T/O4.68MT/O Rate0.14%Tradable Shares163.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
BRIEF-Henlius Says It Entered Strategic Collaboration With Al-Tiryaq Al-Khalawi Medical Company
Reuters  ·  11-09
BRIEF-Henlius Says It Entered Strategic Collaboration With Al-Tiryaq Al-Khalawi Medical Company
Henlius: on Morning of Nov 7, Entered Into a Strategic Collaboration With Al-Tiryaq Al-Khalawi Medical Company
THOMSON REUTERS  ·  11-09
Henlius: on Morning of Nov 7, Entered Into a Strategic Collaboration With Al-Tiryaq Al-Khalawi Medical Company
Henlius: Co and Svax Forge Strategic Partnership in Menat Market, Will Establish Joint Ventures in Saudi Arabia
THOMSON REUTERS  ·  11-09
Henlius: Co and Svax Forge Strategic Partnership in Menat Market, Will Establish Joint Ventures in Saudi Arabia
Henlius to Establish Saudi Arabia JVs to Distribute Drugs to Middle East
MT Newswires Live  ·  11-08
Henlius to Establish Saudi Arabia JVs to Distribute Drugs to Middle East
BRIEF-Shanghai Henlius Biotech Says Biologics License Application For Biosimilar Of Denosumab Hlx14 Accepted By Us FDA
Reuters  ·  10-30
BRIEF-Shanghai Henlius Biotech Says Biologics License Application For Biosimilar Of Denosumab Hlx14 Accepted By Us FDA
US FDA Accepts Biologics License Application (Bla) for Hlx14, Biosimilar Candidate of Prolia/Xgeva (Denosumab)
THOMSON REUTERS  ·  10-30
US FDA Accepts Biologics License Application (Bla) for Hlx14, Biosimilar Candidate of Prolia/Xgeva (Denosumab)
Shanghai Henlius Biotech - Biologics License Application for Biosimilar of Denosumab Hlx14 Accepted by US FDA
THOMSON REUTERS  ·  10-30
Shanghai Henlius Biotech - Biologics License Application for Biosimilar of Denosumab Hlx14 Accepted by US FDA
Shanghai Henlius Biotech Doses 1st Patient in Metastatic Colorectal Cancer Drug in Japan
MT Newswires Live  ·  10-24
Shanghai Henlius Biotech Doses 1st Patient in Metastatic Colorectal Cancer Drug in Japan
Organon, Henlius Say Phase 3 Trial of Perjeta Biosimilar Meets Primary Endpoint
MT Newswires Live  ·  09-30
Organon, Henlius Say Phase 3 Trial of Perjeta Biosimilar Meets Primary Endpoint
Shanghai Henlius Biotech - International Multi-Center Phase 3 Clinical Study of Hlx11 Met Primary Study Endpoint
THOMSON REUTERS  ·  09-27
Shanghai Henlius Biotech - International Multi-Center Phase 3 Clinical Study of Hlx11 Met Primary Study Endpoint
Shanghai Henlius Biotech H1 Operating Income RMB 2,746.1 Million
THOMSON REUTERS  ·  09-26
Shanghai Henlius Biotech H1 Operating Income RMB 2,746.1 Million
BRIEF-Shanghai Henlius Biotech Says Serplulimab Injection Received Positive Opinion
Reuters  ·  09-21
BRIEF-Shanghai Henlius Biotech Says Serplulimab Injection Received Positive Opinion
Shanghai Henlius Biotech - Opinion From Committee for- Medicinal Products for Human Use of European Medicines Agency
THOMSON REUTERS  ·  09-20
Shanghai Henlius Biotech - Opinion From Committee for- Medicinal Products for Human Use of European Medicines Agency
BRIEF-Morgan Stanley's Long Position Shanghai Henlius Biotech H-Shares Reduces To 1.04% On Sept 3 - HKEX
Reuters  ·  09-09
BRIEF-Morgan Stanley's Long Position Shanghai Henlius Biotech H-Shares Reduces To 1.04% On Sept 3 - HKEX
Morgan Stanley's Long Position in H-Shares of Shanghai Henlius Biotech Decreases to 1.04% on Sept 3 From 5.77% - HKEX
THOMSON REUTERS  ·  09-09
Morgan Stanley's Long Position in H-Shares of Shanghai Henlius Biotech Decreases to 1.04% on Sept 3 From 5.77% - HKEX
Shanghai Henlius Biotech Gets Regulatory Nod for Clinical Trial of Cancer Drug in China
MT Newswires Live  ·  09-02
Shanghai Henlius Biotech Gets Regulatory Nod for Clinical Trial of Cancer Drug in China
Shanghai Henlius Biotech Inc - Application for Clinical Trial Approved by Nmpa of China
THOMSON REUTERS  ·  09-02
Shanghai Henlius Biotech Inc - Application for Clinical Trial Approved by Nmpa of China
Shanghai Henlius Biotech - Clinical Trial of Pembrolizumab Biosimilar Hlx17 (Recombinant- Humanised Anti-Pd-1 Monoclonal Antibody Injection) Approved
THOMSON REUTERS  ·  09-02
Shanghai Henlius Biotech - Clinical Trial of Pembrolizumab Biosimilar Hlx17 (Recombinant- Humanised Anti-Pd-1 Monoclonal Antibody Injection) Approved
BRIEF-Shanghai Henlius Biotech Does Not Recommend Distribution Of Any Interim Dividend
Reuters  ·  08-26
BRIEF-Shanghai Henlius Biotech Does Not Recommend Distribution Of Any Interim Dividend
Shanghai Henlius Biotech Records Higher Profit in H1
MT Newswires Live  ·  08-26
Shanghai Henlius Biotech Records Higher Profit in H1

Introduction

Company Name.
HENLIUS
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Shanghai Henlius Biotech Inc. is a China-based company principally involved in the research, development, production and sales of monoclonal antibody products. The Company’s main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) biosimilar HLX02, Humira (adalimumab) biosimilar HLX03 and Avastin (bevacizumab) biosimilar HLX04, as well as bio-innovative drug candidates, including HLX06 (a novel VEGFR2 inhibitor), HLX07 (an EGFR inhibitor), HLX10 (a novel PD-1 inhibitor), HLX20 (a novel PD-L1 inhibitor) and HLX22 (a novel HER2 inhibitor), among others. The Company is also engaged in the provision of related technical services. The Company operates its businesses primarily in Mainland China and the United States.
Issue price:
--